» Articles » PMID: 25633985

The Role of the Mammalian DNA End-processing Enzyme Polynucleotide Kinase 3'-phosphatase in Spinocerebellar Ataxia Type 3 Pathogenesis

Abstract

DNA strand-breaks (SBs) with non-ligatable ends are generated by ionizing radiation, oxidative stress, various chemotherapeutic agents, and also as base excision repair (BER) intermediates. Several neurological diseases have already been identified as being due to a deficiency in DNA end-processing activities. Two common dirty ends, 3'-P and 5'-OH, are processed by mammalian polynucleotide kinase 3'-phosphatase (PNKP), a bifunctional enzyme with 3'-phosphatase and 5'-kinase activities. We have made the unexpected observation that PNKP stably associates with Ataxin-3 (ATXN3), a polyglutamine repeat-containing protein mutated in spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph Disease (MJD). This disease is one of the most common dominantly inherited ataxias worldwide; the defect in SCA3 is due to CAG repeat expansion (from the normal 14-41 to 55-82 repeats) in the ATXN3 coding region. However, how the expanded form gains its toxic function is still not clearly understood. Here we report that purified wild-type (WT) ATXN3 stimulates, and by contrast the mutant form specifically inhibits, PNKP's 3' phosphatase activity in vitro. ATXN3-deficient cells also show decreased PNKP activity. Furthermore, transgenic mice conditionally expressing the pathological form of human ATXN3 also showed decreased 3'-phosphatase activity of PNKP, mostly in the deep cerebellar nuclei, one of the most affected regions in MJD patients' brain. Finally, long amplicon quantitative PCR analysis of human MJD patients' brain samples showed a significant accumulation of DNA strand breaks. Our results thus indicate that the accumulation of DNA strand breaks due to functional deficiency of PNKP is etiologically linked to the pathogenesis of SCA3/MJD.

Citing Articles

Intersection of the fragile X-related disorders and the DNA damage response.

Kumari D, Grant-Bier J, Kadyrov F, Usdin K DNA Repair (Amst). 2024; 144:103785.

PMID: 39549538 PMC: 11789500. DOI: 10.1016/j.dnarep.2024.103785.


ATXN3: a multifunctional protein involved in the polyglutamine disease spinocerebellar ataxia type 3.

Hernandez-Carralero E, Quinet G, Freire R Expert Rev Mol Med. 2024; 26:e19.

PMID: 39320846 PMC: 11440613. DOI: 10.1017/erm.2024.10.


Fructose-2,6-bisphosphate restores DNA repair activity of PNKP and ameliorates neurodegenerative symptoms in Huntington's disease.

Chakraborty A, Sreenivasmurthy S, Miller W, Huai W, Biswas T, Mandal S Proc Natl Acad Sci U S A. 2024; 121(39):e2406308121.

PMID: 39298485 PMC: 11441552. DOI: 10.1073/pnas.2406308121.


Spinocerebellar ataxias: from pathogenesis to recent therapeutic advances.

Cui Z, Mao Z, Yang R, Li J, Jia S, Zhao J Front Neurosci. 2024; 18:1422442.

PMID: 38894941 PMC: 11185097. DOI: 10.3389/fnins.2024.1422442.


Oxidative Stress in Spinocerebellar Ataxia Type 3 and Its Attenuation by Herbal Remedies in Traditional Chinese Medicine: A Systematic Review.

Mohd Hisam N, Wong K Antioxidants (Basel). 2024; 13(3).

PMID: 38539908 PMC: 10968558. DOI: 10.3390/antiox13030375.


References
1.
Plo I, Liao Z, Barcelo J, Kohlhagen G, Caldecott K, Weinfeld M . Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair (Amst). 2003; 2(10):1087-100. DOI: 10.1016/s1568-7864(03)00116-2. View

2.
Whitehouse C, Taylor R, Thistlethwaite A, Zhang H, Karimi-Busheri F, Lasko D . XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell. 2001; 104(1):107-17. DOI: 10.1016/s0092-8674(01)00195-7. View

3.
Chai Y, Berke S, Cohen R, Paulson H . Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways. J Biol Chem. 2003; 279(5):3605-11. DOI: 10.1074/jbc.M310939200. View

4.
Schols L, Bauer P, Schmidt T, Schulte T, Riess O . Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 2004; 3(5):291-304. DOI: 10.1016/S1474-4422(04)00737-9. View

5.
Costa M, Gomes-da-Silva J, Miranda C, Sequeiros J, Santos M, Maciel P . Genomic structure, promoter activity, and developmental expression of the mouse homologue of the Machado-Joseph disease (MJD) gene. Genomics. 2004; 84(2):361-73. PMC: 2894082. DOI: 10.1016/j.ygeno.2004.02.012. View